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ABSTRACT The surface capsular polysaccharide (CP) is a virulence factor that has been used as an antigen in several successful
vaccines against bacterial pathogens. A vaccine has not yet been licensed against Staphylococcus aureus, although two multicom-
ponent vaccines that contain CP antigens are in clinical trials. In this study, we evaluated CP production in USA300methicillin-
resistant S. aureus (MRSA) isolates that have become the predominant community-associated MRSA clones in the United States.
We found that all 167 USA300MRSA and 50 USA300 methicillin-susceptible S. aureus (MSSA) isolates were CP negative (CP).
Moreover, all 16 USA500 isolates, which have been postulated to be the progenitor lineage of USA300, were also CP. Whole-
genome sequence analysis of 146 CPUSA300MRSA isolates revealed they all carry a cap5 locus with 4 conserved mutations
compared with strain Newman. Genetic complementation experiments revealed that three of these mutations (in the cap5 pro-
moter, cap5D nucleotide 994, and cap5E nucleotide 223) ablated CP production in USA300 and that Cap5E75 Asp, located in the
coenzyme-binding domain, is essential for capsule production. All but three USA300MSSA isolates had the same four cap5mu-
tations found in USA300MRSA isolates. Most isolates with a USA500 pulsotype carried three of these four USA300-specific mu-
tations, suggesting the fourth mutation occurred in the USA300 lineage. Phylogenetic analysis of the cap loci of our USA300 iso-
lates as well as publicly available genomes from 41 other sequence types revealed that the USA300-specific cap5mutations arose
sequentially in S. aureus in a common ancestor of USA300 and USA500 isolates.
IMPORTANCE The USA300MRSA clone emerged as a community-associated pathogen in the United States nearly 20 years ago.
Since then, it has rapidly disseminated and now causes health care-associated infections. This study shows that the CP-negative
(CP) phenotype has persisted among USA300 isolates and is a universal and characteristic trait of this highly successful MRSA
lineage. It is important to note that a vaccine consisting solely of CP antigens would not likely demonstrate high efficacy in the
U.S. population, where about half of MRSA isolates comprise USA300. Moreover, conversion of a USA300 strain to a CP-positive
(CP) phenotype is unlikely in vivo or in vitro since it would require the reversion of 3 mutations. We have also established that
USA300MSSA isolates and USA500 isolates are CP and provide new insight into the evolution of the USA300 and USA500 lin-
eages.
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Staphylococcus aureus is an important pathogen that causes awide range of infections in health care and community set-
tings. Methicillin-resistant S. aureus (MRSA) isolates in particu-
lar, which have become increasingly prevalent in the last decade,
are resistant to nearly all -lactams and are often multiply resis-
tant to several classes of antibiotics. A vaccine that could protect
against S. aureus infection would be important for public health,
although development of an effective vaccine has remained elu-
sive (1, 2).
Capsular polysaccharides (CPs) envelope the surface of many
bacterial pathogens and have been the primary or sole protective
antigen used in vaccines that are effective against certain serotypes
of Streptococcus pneumoniae, Haemophilus influenzae, and Neisse-
ria meningitidis (serotypes A, CW, and Y) (3). Among encapsu-
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lated S. aureus isolates, serotypes 5 and 8 prevail (4–9). Capsular
polysaccharides 5 (CP5) and 8 (CP8) have similar trisaccharide
repeating units but differ in the linkages between the sugars and
the sites of O-acetylation of the monosaccharide residues (10).
Previous reports have indicated that ~20% of S. aureus isolates fail
to produce CP5 or CP8 (4–9).
The S. aureus CP protects the bacterium from host phagocytes
(2); however, this protection can be overcome by CP-specific an-
tibodies that enhance opsonophagocytic killing by human neutro-
phils (10, 11). Vaccines that contained CP5 and CP8 antigens
conjugated to Pseudomonas aeruginosa exotoxoid A were tested
for efficacy in patients with end-stage renal disease. In phase III
clinical trials, these CP-based vaccines failed to protect against
S. aureus bacteremia (12–14).
In the United States, the community-associated (CA)-MRSA
clonal type USA300 has been the most frequently isolated S. au-
reus genotype from all body sites, including blood, surpassing the
USA100 health care-associated MRSA strain type as a cause of
nosocomial infection in some locales (15). USA300 MRSA strains
are most often associated with CA skin and soft tissue infection
(SSTI) (16) and belong to multilocus sequence type 8 (ST8).
USA300 MRSA isolates characteristically contain the SCCmec
type IV element (17), a phage carrying the genes encoding Panton-
Valentine leukocidin (PVL) (18) and the arginine catabolic mo-
bile genetic element (ACME) carrying the arginine deiminase
cluster and the gene encoding the spermidine resistance factor,
SpeG, which promotes skin colonization (19–21). Although they
usually lack SCCmec IV, ACME, and PVL, USA500 MRSA isolates
are the closest relative of USA300 among the members of the ST8
lineage and have been postulated to be the progenitor of USA300
(21).
We previously demonstrated that neither CP5 nor CP8 was
produced by several USA300 MRSA clinical isolates obtained in
2004 and 2005 from our center in Chicago, IL (22). A subsequent
study of isolates obtained during the same time period (2004 to
2005) from Washington, DC, also reported CP-negative (CP)
USA300 MRSA strains (23). These studies suggested that the fail-
ure to produce a CP was a common trait among USA300 MRSA
isolates circulating in 2004 through 2005, but this was not inves-
tigated subsequently.
A decade has passed since the CP USA300 MRSA isolates
were described. Since then, USA300 MRSA strains have widely
disseminated and increased in prevalence in the United States
(15). It is not known if there are CP5-positive (CP5) USA300
variants in circulation or if the CPUSA300 MRSA isolates iden-
tified in 2004 have become the sole or dominant USA300 clone.
Because CP5 and CP8 are components in two S. aureus vac-
cines under development (1, 24, 25), the aim of this study was to
determine if currently circulating USA300 MRSA isolates produce
a CP. Further, we evaluated whether the CP phenotype was
shared by USA300 methicillin-susceptible S. aureus (MSSA) iso-
lates and the closely related USA500 lineage (21, 26). Since we
found that all USA300 and USA500 isolates were uniformly CP,
we analyzed the evolutionary relationship between the cap5 mu-
tations in USA300 and USA500 isolates.
(This work was presented in part at the International Sympo-
sium on Staphylococci and Staphylococcal Infections, Chicago,
IL, 2014.)
RESULTS
CP serotyping. We chose for CP serotyping 233 clinical S. aureus
isolates from our collection that were identified as either USA300
MRSA, USA300 MSSA, or USA500. Isolates were obtained from
either colonized or infected body sites from subjects in Chicago,
IL, Los Angeles, CA, San Francisco, CA, or Connecticut between
1995 and 2011, as described in Table 1. Clonal types consisted of
(i) 167 USA300 MRSA isolates, (ii) 50 USA300 MSSA isolates, (iii)
14 USA500 MRSA isolates, and (iv) 2 USA500 MSSA isolates. The
USA300 sample included 16 ACME arcA-negative USA300 MRSA
isolates and 38 ACME arcA-negative USA300 MSSA isolates (as
detailed in Table S1 in the supplemental material), since the ab-
sence of ACME arcA is atypical compared with other USA300
strains, and these isolates might exhibit altered CP phenotypes.
Table S1 provides the typing characteristics of USA300 MSSA iso-
lates, USA500 isolates, and ACME arcA-negative USA300 isolates.
USA300 MRSA and MSSA isolates. Capsule production was
evaluated in 167 USA300 MRSA isolates. Although all USA300
MRSA strains tested carried a cap5 locus, all were nonreactive to
CP5 polyclonal antiserum, whereas the CP5 control strains
Reynolds and Newman produced a signal (Fig. 1). Figure 1 also
shows the nonreactivity to CP5 antiserum of the CP8 strains,
ST80 and MN8, as well as the CP strains NCTC 8325-4 (27) and
USA300 strain LAC. All 9 MRSA isolates that had a pulsotype
consistent with USA300 but lacked ACME arcA were also CP.
USA300 MRSA isolates were nonreactive with CP8 polyclonal an-
tiserum, as expected, since they do not encode a cap8 locus (data
not shown). All 50 USA300 MSSA isolates tested were CP.
To address the possibility that USA300 strains might produce
CP5 in vivo but not in vitro, we performed experiments similar to
those described previously (28, 29). Both strain Newman and the
USA300 MRSA strain CDC3 reacted with antibodies raised to
TABLE 1 Demographics of USA300 and USA500 clinical isolates
Parameter
No. of isolates
USA300 USA500
MRSA MSSA Total MRSA MSSA Total
Colonization vs
infection
Colonization 134 20 154 0 0 0
Infection 33 30 63 14 2 16
Total 167 50 217 14 2 16
Geographic source
Chicago 83 45 128 12 0 12
Los Angeles 84 3 87 1 0 1
San Francisco 0 2 2 0 2 2
Connecticut 0 0 0 1a 0 1
Total 167 50 217 14 2 16
Yr of isolation
1995 1 0 1 0 0 0
1996 0 0 0 5 0 5
1997 0 0 0 2 0 2
2004 1 0 1 0 0 0
2008 37 0 37 5 0 5
2009 92 17 109 0 2 2
2010 33 21 54 0 0 0
2011 3 12 15 0 0 0
Unknown 0 0 0 2 0 1
Total 167 50 217 14 2 16
a This isolate is the USA500 reference strain NRS385.
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killed acapsular S. aureus cells (see Fig. S1 in the supplemental
material). The control CP5 strain Newman produced CP5 as
visualized by the blue-staining Alexa Fluor 660-tagged second-
ary antibodies reacting with CP5 antibodies. In contrast, nei-
ther the inoculum of USA300 MRSA strain CDC3 nor the
CDC3 bacteria isolated from mouse blood 6 h after bacterial
challenge showed detectable reactivity with the CP5 antibodies.
Similar results were obtained with samples of blood from mice
challenged with USA300 strain LAC. Thus, our results show no
evidence that USA300 MRSA isolates produce CP5 in vivo.
USA500 isolates. Due to the close phylogenetic relationship
between USA500 and USA300 isolates (21, 30), we hypothesized
that USA500 isolates might also be CP5. Figure 2 documents the
pulsed-field gel electrophoresis (PFGE) patterns and relevant typ-
ing characteristics of the 16 USA500 isolates we tested for CP
production. The USA500 isolates belonged to ST8, carried
SCCmec type IV, and lacked ACME arcA (26, 30, 31) (see Ta-
ble S1 in the supplemental material). However, most of these
USA500 isolates carried pvl genes, which is atypical for USA500.
The USA500 isolates belonged to three spa types: t064 (11 of 16
isolates), t008 (n  3), or t211 (n  2) (see Table S1). All 16
USA500 isolates were CP as represented in a panel in Fig. 1.
DNA sequence analysis of cap loci ofUSA300MRSA isolates.
To evaluate the genetic basis for the CP5 phenotype, we evalu-
ated the cap loci from assembled whole-genome shotgun data
from 146 CP USA300 MRSA isolates. Each strain carried an in-
tact cap5 locus but had 4 identical point mutations relative to the
CP5 reference strain Newman (Fig. 3A).
The cap5 promoter had a T¡C replacement 73 bp upstream
(73) from the ATG translation start codon of cap5A (Pcap573).
This was located in the cap5 promoter in an inverted repeat
(Fig. 3) known to be essential for transcription of capABCDEF (27,
32). We also identified a frameshift mutation within a polyad-
enine (AA) tract that begins at nucleotide (nt) 1006 of cap5D in
strain Newman. This corresponds to nt 994 in cap5D of the
USA300 reference strain because the annotations for the start
codon of strain Newman and USA300 differ by four codons. This
segment contains six A’s in the wild-type (wt) cap5D gene (strain
Newman) and seven A’s in USA300 MRSA isolates, resulting in
premature termination during translation (after 338 residues of
the full-length Newman protein and 334 residues in USA300).
There was also a G¡T mutation at position 223 of cap5E (cap5E-
223), which converts Asp to Tyr in the encoded protein at codon
75 (Asp75Tyr) and a T¡C mutation in cap5G-478, resulting in a
Phe160Leu conversion in the encoded protein. Additional non-
conserved mutations were found in various cap5 genes among
USA300 isolates (data not shown) (33). The mutations in USA300
at cap5E-223 and cap5G-478 have not been previously recognized
in USA300 isolates, whereas the mutations in Pcap5 and cap5D
FIG 1 CP immunoblots of USA300 and USA500 clinical isolates. Capsule
serotyping was performed by a colony immunoblot method with the use of
CP5-specific antibodies as described previously (43). The first row shows the
results from the CP5-positive (CP5) control strains Reynolds and Newman,
the CP5- and CP8-negative (CP) control strains LAC and 8325, and the
CP8 control strains ST80 and MN8. The second and third rows include six
representative USA300 and USA500 clinical isolates, respectively.
FIG 2 Pulsed-field gel electrophoresis (PFGE) documenting the SmaI digestion patterns of USA500 isolates relative to the USA500 reference strain NRS385
(USA500ref) and relevant typing characteristics. The USA300 reference strain (USA300ref) has PFGE pattern USA300-0114 and was obtained from the Network
for Antimicrobial Resistance in Staphylococcus aureus (NARSA). “Cp5/8” refers to capsule polysaccharide types 5 and 8, “CapE 223” refers to the nucleotide at
position 223 in cap5E, and “CapG 478” refers to the nucleotide at position 478 in cap5G.
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were identified previously in three USA300 MRSA isolates from
2004 to 2005 (22).
cap5 loci in publicly available USA300 S. aureus genome se-
quences. To confirm that the USA300-specific mutations were
not confined to the Chicago and Los Angeles locales, we also an-
alyzed 319 previously published USA300 isolate sequences from
San Diego, CA (n 35), and New York (n 277). (Annotations
of the included isolates are outlined in Table S2 in the supplemen-
tal material.) All but one isolate had all 4 cap5 mutations identical
to those in our USA300 collection.
cap5 mutations among USA300 arcA-negative MRSA and
USA300MSSA isolates.We performed Sanger sequencing of PCR
products amplified from the cap5 locus to determine if the four
cap5 mutations identified in USA300 MRSA isolates were also
conserved among 9 atypical USA300 MRSA isolates that were
ACME arcA negative and 19 USA300 MSSA isolates (Table 2). All
4 USA300-specific mutations were conserved among 8 of 9 (89%)
ACME arcA-negative USA300 MRSA isolates tested (Table 2).
One USA300 MRSA outlier (isolate 111395F) had only 2 of the 4
cap mutations (Pcap5 73 and cap5D-994). However, this isolate
FIG 3 USA300 cap5 locus showing universal mutations in USA300 relative to the cap5 reference strain Newman. Orange arrows depict open reading frames
(ORFs). “Pcap5” refers to the cap5 promoter region. The inverted repeat sequence, as reported by Ouyang et al. (32), is shown as opposing arrows beneath Pcap5
indicating the T¡C mutation in strain USA300 relative to strain Newman. The yellow line indicates a disruption of the cap5D ORF due to insertion of an A at
nt 994 in USA300 (994AA). The cap5E G¡T mutation at nt 223 (G223T) and the cap5G T¡C mutation at nt 478 (T478C) are indicated beneath each ORF. (B)
Lines beneath the map indicate the cap5 regions from strain Newman that are cloned in the complementation plasmids pKOR19 (cap5ABC plus truncated
cap5D), pKOR18 (cap5ABCD plus a portion of cap5E), pCap16 (cap5ABCDE), and pCap17 (which contains cap5ABCDEF). (C) CP5 serotyping results from
USA300 MRSA strain 923 transformants harboring the cap5 complementation plasmids depicted in panel B.
TABLE 2 Summary of conserved mutations in cap5 loci detected in USA300 and USA500 isolates in our collectiona
Gene
nt
position
nt in: Codon (aa) in:
Codon
position
nt (no./total)
Strain
Newman USA300
Strain
Newman USA300
USA300 USA500
MRSA
ACME arcA
(n 155)b
MRSA
ACME arcA
(n 9)c
MSSA
(n 19)c
MRSA
(n 14)c
MSSA
(n 2)c
Pcap5d 73e T C NAf NA NA C (155/155) C (9/9) C (19/19) C (14/14) C (2/2)
cap5D 994g A AA AAA (Lys) STOP 338 AA (155/155) AA (9/9) AA (19/19) AA (14/14) AA (2/2)
cap5E 223 G T GAT (Asp) TAT (Tyr) 75 T (155/155) T (8/9) T (16/19) G (14/14) G (2/2)
G (1/9) G (3/19)
cap5G 478 T C TTC (Phe) CTC (Leu) 160 C (155/155) C (8/9) C (10/19) C (11/14) T (2/2)
T (1/9) T (3/14)
a SNPs of clinical isolates subjected to whole-genome sequencing or Sanger sequencing of PCR products as described in the text.
b USA300 ACME arcA MRSA isolates were characterized by PFGE or by molecular typing as described in Materials and Methods.
c Details of the molecular typing characteristics are provided in Table S1 in the supplemental material.
d Pcap5, promoter region of the cap5 operon.
e Seventy-three nucleotides upstream of the cap5A ATG translation initiation codon.
f NA, not applicable since the polymorphism is in an intergenic region.
g cap5D nt 994 in the USA300 reference strain corresponds to cap5D nt 1006 in strain Newman.
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was obtained in 1995 and is not typical of recent USA300 MRSA
isolates. Although isolate 111395F had a SmaI digestion pattern
similar to that of a USA300 isolate, it had features consistent with
USA500 isolates, including spa type t064, ACME arcA, and PVL.
However, strain 111395F also had features atypical for USA500,
including carriage of SCCmec II.
Among the USA300 MSSA isolates tested, 16 of 19 (84.2%) had
all 4 USA300-specific mutations in Pcap5, cap5D-994, cap5E-223,
and cap5G-478 (Table 2; see Table S1 in the supplemental mate-
rial). Three outlier MSSA isolates had just three of the USA300-
specific mutations (Pcap5, cap5D-994, and cap5G-478).
USA500 isolates. Among USA500 isolates, the four USA300
cap5 mutations described above were common but not universal.
By Sanger sequencing, we found that 11 of the 14 (78%) USA500
MRSA isolates had 3 of the 4 USA300-specific mutations (Pcap5
73, cap5D-994, and capG-478), and none had the G¡T muta-
tion at cap5E-223. Three outlier USA500 MRSA isolates and both
USA500 MSSA isolates had only 2 of the 4 mutations (Pcap573
and cap5D-993) (Table 2), but these are each sufficient to yield a
CP phenotype (27).
Analysis of USA300-specific cap5 mutations in S. aureus
phylogenies.To evaluate the appearance of the cap5 mutations on
the core phylogeny of S. aureus, we analyzed the USA300-specific
cap5 mutations in 319 publicly available USA300 S. aureus ge-
nome sequences, 146 USA300 MRSA genomes in this study, and
90 non-USA300 genomes from 41 STs (Fig. 4). This allowed us to
propose that the USA300 cap5 mutations evolved in a stepwise
fashion. Moreover, these data suggest that USA300 and USA500
appear to have emerged from a common ancestor, and the Pcap5
T¡C mutation likely occurred in the last common ancestor
(LCA) of all USA300 and USA500 strains. The cap5D insertion
may also have occurred in the LCA of both USA300 and USA500
but may have reverted back to wt in a recently emerged branch
within USA500 (exemplified by strains GA231 and GA27). The
cap5G T¡C mutation had its origins in an ancestor of all USA300
strains that was also a progenitor of a clade of strains falling be-
tween the classical USA300 and USA500 patterns.
Our analysis also suggests that the isolates with ST609 and
ST623 are intermediate between USA300 and USA500 and might
have a common ancestry. The conserved cap5 mutations that we
describe were not present in any of the other 20 clonal complexes
and were not in all ST8 strains. Thus, these mutations are unique
to USA300 and its close relatives USA500, ST609, and ST623.
Complementation studies to test the phenotypic effect of
cap5 gene mutations. To determine the phenotypic relevance of
the cap5 single nucleotide polymorphisms (SNPs) in strain
USA300, we tested whether expression of wild-type cap5 genes in
trans on a complementation plasmid could restore CP5 produc-
tion to USA300 MRSA strain 923. The cap5 genes included in each
complementation plasmid are depicted in Fig. 3B. Transforma-
tion of USA300 strain 923 with pKOR19 (expressing wt cap5ABC)
or pKOR18 (expressing wt capABCD) was not sufficient to restore
the CP5 phenotype (Fig. 3C). This was not due to mutations in
the cloned cap5 promoter or cap5D, as confirmed by DNA se-
quence analysis. In contrast, transformation of USA300 strain 923
with pCap16 (expressing wt cap5ABCDE) or pCap17 (wt
cap5ABCDEF genes) restored CP5 production (Fig. 3C). These
data indicate that the mutations in cap5D and Pcap5 in USA300 and
USA500 strains ablate CP production. These data also reveal a
vital role for the Asp¡Tyr substitution at Cap5E-75 in ablating
CP production. In contrast, Cap5G tolerates the Phe160Leu sub-
stitution in USA300 because complementation of CP5 production
in a USA300 strain was achieved by a plasmid lacking cap5G.
DISCUSSION
The fact that CP antigens have been used successfully in vaccines
against several bacterial pathogens has encouraged a similar vac-
cine strategy for S. aureus. Several vaccines that have been de-
signed for use against S. aureus have included CP5 and CP8 be-
cause they are the most common CP types produced by S. aureus
clinical isolates. However, this study shows that USA300 MRSA
isolates, as well as USA300 MSSA and closely related USA500 iso-
lates, are universally CP negative. We also showed no evidence
that USA300 isolates produce CP5 in vivo during infection in
mice. In contrast, Timofeyeva et al. demonstrated that CP5 was
detected in vivo on USA300 MRSA after a 6-h infection (28). We
cannot explain the discrepancy between the two studies. However,
it is unlikely that a strain could revert all 3 mutations that would be
required for USA300 to revert to a CP phenotype.
USA300 isolates have increased in prevalence in the United
States to become one of the most common S. aureus genotypes
(15), especially among SSTIs, where they have accounted for 98%
of MRSA isolates (16). Because USA300 isolates comprise a sub-
stantial portion of the S. aureus disease burden in the United
States, a vaccine based solely on CP would likely demonstrate low
efficacy in a U.S. population.
These results extend the observations reported a decade ago
when USA300 MRSA isolates were first reported to be acapsular
(22, 23). We now show that the CP phenotype has persisted
among USA300 MRSA isolates and is a universal and characteris-
tic trait of this highly successful MRSA lineage. Moreover, we have
now established that USA300 MSSA isolates and USA500 isolates
are also CP.
Our prior understanding of the genetic basis of the CP phe-
notype among USA300 isolates was limited to our identification of
two mutations in the cap5 locus in three USA300 isolates (22) that
had been shown previously to ablate CP production in other S. au-
reus strains (27, 32). The comprehensive genetic analyses of
USA300 isolates in this study reveals that the 4 cap5 mutations are
present in all but 1 USA300 MRSA isolate and in all but 3 USA300
MSSA isolates. Importantly, 3 of those 4 mutations are alone suf-
ficient to ablate CP production. It would therefore require rever-
sion of all 3 mutations in USA300 MRSA to produce a strain that
produces a CP. Also, 3 of the 4 same mutations are common in the
USA500 lineage. It has been shown previously that the mutations
in Pcap5 73 and the frameshift mutation in cap5D ablate CP
production in S. aureus (22, 27). Whereas the promoter mutation
attenuates expression of capABCDEF, the cap5D and cap5E muta-
tions ablate production or activity of enzymes responsible for pro-
ducing key soluble precursors UDP-D-FucNAc and UDP-L-
FucNAc, respectively, that are needed for the biosynthesis of CP
(2, 34). This is the first report to show that Asp75 is a critical
residue in Cap5E, which is an essential enzyme for CP5 produc-
tion (35). This enzyme converts the precursor (UDP-GlcNAc) to a
keto-intermediate that is further reduced (by Cap5F) and epimerized
at C-2 (by Cap5G) to yield UDP-N-acetyl L-fucosamine (36). Thus,
USA300 is unable to produce UDP-N-acetyl L-fucosamine, which is
required for CP5 and CP8 production. When the Cap5E Asp75Tyr
conversion is overlaid on the Cap5E three-dimensional crystal struc-
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FIG 4 A maximum likelihood phylogeny based on whole-genome alignments of publicly available S. aureus genomes. (A) Phylogenetic analysis of 104 S. aureus
strains from 41 STs showing the distribution of conserved mutations in cap5 in USA300 (Table 2). There are 14 USA300 strains in the tree that are representative
of 146 strains from our study and 319 publicly available USA300 genomes. The remaining 90 genomes are from non-USA300 isolates. Strain names are shown
as either the common name or the accession number followed by the sequence type (ST) in parentheses. Strains with red and blue text, respectively, are previously
confirmed USA300 and USA500 isolates. The clade in orange is clonal complex 8 (CC8). Other common CCs are also highlighted. For simplicity, only a
representative strain from each ST with the same pattern of cap5 mutations was included. Carriage of PVL and ACME is indicated with black and red diamonds,
respectively, due to their association with the USA300 subclone. cap5 mutations are shown as solid or open circles as indicated. (B) High-resolution phylogeny
of CC8 strains (a subset from panel A). USA300 and USA500 strains are annotated as in panel A.
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ture (37), it lies within the coenzyme-binding domain. This informa-
tion could be useful in developing inhibitors of CP biosynthesis.
Our analysis of S. aureus whole-genome sequences (WGSs) in
the public databases from 41 STs also provides insight into the
evolution of the USA500 and USA300 S. aureus lineages not pre-
viously appreciated. All USA500 isolates that we evaluated had at
least 2 of the 4 cap5 mutations found in USA300 MRSA (in Pcap5
and in cap5D—both essential for CP production [36]). Moreover,
most USA500 MRSA isolates had the cap5G478 T¡C mutation.
Notably, because none of the USA500 isolates had the cap5E-223
G¡T mutation, this is a feature in the core genome that might be
used to distinguish USA500 from USA300 isolates in future epi-
demiological studies. By overlaying the USA300 mutations on the
phylogeny of S. aureus genomes (Fig. 4), it is apparent that the 4
USA300 cap5-specific mutations only exist in clonal cluster 8, and
they arose sequentially, starting with Pcap5, in a common ancestor
of USA300 and USA500 isolates. Importantly, this is the first study
to reveal that USA300 and USA500 lineages inherited the cap mu-
tations from a common ancestor rather than USA300 inheriting
them from USA500, as suggested previously (21).
MRSA isolates arise by horizontal acquisition of a mobile ge-
netic element called SCCmec that carries the methicillin resistance
gene, mec (18). Interestingly, only a limited number of genetic
backgrounds have become successful MRSA clones (18). Despite
the close genetic similarity between the USA300 and USA500 lin-
eages (21, 26, 30), USA300 has disseminated more widely in the
United States. Comparisons of virulence factors produced by
USA500 versus USA300 may provide insight into their relative
successes. USA500 and USA300 MRSA isolates both exhibit high-
level virulence in animal infection (22, 26, 30), and both express
high levels of global regulators and exotoxins encoded in the core
genome (22, 26). CP is another core virulence determinant that we
have ruled out as a key player in the relative success of USA300
over USA500, because CP is not expressed in either subclone. The
success of USA300 may lie in the fact that it carries ACME, which
is thought to enhance transmissibility and competitiveness of
USA300, although not its virulence (19, 20, 22).
Our findings shed light on the roles of CP5 and CP8 in staph-
ylococcal virulence of USA300 and USA500 strains. CP has been
shown to protect S. aureus from opsonophagocytic killing by hu-
man neutrophils (11, 29) and thus protects S. aureus from host
immune killing. Moreover, the capsule has been shown to en-
hance virulence in animal models of bacteremia, subcutaneous
and renal abscess formation, surgical wound infection, septic ar-
thritis, and lethality (2). Yet its absence in USA300 and USA500
strains underscores the fact that a CP is not necessary for virulence
of these strains. This is consistent with studies that have shown
that CP production can attenuate staphylococcal virulence in sit-
uations in which bacterial adherence is critical, as in endocarditis
and murine mastitis, because it masks the adhesins on the cell
surface (2). USA300 is best known for causing SSTIs, so we can
speculate that perhaps this niche favors a CP phenotype by ex-
posing adhesins on the surface of the bacteria. Because the patho-
genesis of staphylococcal infections is multifactorial, it is likely
that other virulence factors produced by USA300 and USA500
compensate for lack of CP during infection. Overexpression of
agr, sae, -hemolysin, and a variety of leukocidins (22), may even
have been selected for in the absence of a CP.
Our study has limitations. Our sample of isolates was obtained
mainly from patients in Chicago and Los Angeles. This was offset
by analyzing public genome sequences, which supported and ex-
tended the findings from our isolates.
We conclude that a vaccine designed for a U.S. population
should not be solely based on CP antigens because USA300 and
USA500 CP isolates cause a large proportion of S. aureus infec-
tions.
MATERIALS AND METHODS
Determination of USA300 and USA500 genetic backgrounds. S. aureus
isolates were confirmed with a catalase test and by agglutination using
Staphaurex Plus (Remel) and underwent genotyping by multilocus se-
quence typing (MLST) (38), Ridom spa typing (39), SCCmec typing (40),
and PCR detection of mecA, the ACME-borne arcA gene (ACME arcA)
(19), and genes encoding PVL (41) as described previously (39). USA300
MRSA isolates were classified by SmaI digestion patterns using pulsed-
field gel electrophoresis (PFGE) as described previously (39). In the ab-
sence of PFGE data, the USA300 genotype was inferred in MRSA isolates
that belonged to ST8 and carried SCCmec type IV and PVL genes (39). All
USA500 isolates and USA300 MSSA isolates were identified solely by
PFGE using SmaI digestion patterns. PFGE patterns were assigned to a
given clonal group by comparison to a reference strain using an 80%
similarity cutoff using the Dice coefficient in BioNumerics software (Ap-
plied Maths, TX) (42). Isolates were obtained from consenting patients as
approved by the Institutional Review Board of the participating institu-
tions.
CP5 and CP8 serotyping. Capsule serotyping was performed by a
colony immunoblot method with the use of CP5- and CP8-specific poly-
clonal antibodies as described (43). Briefly, tryptic soy agar plates were
spot inoculated in a grid pattern with up to 60 S. aureus isolates and
incubated overnight at 37°C. The colonies were blotted onto nitrocellu-
lose filter membranes (diameter, 82.5 mm) for 5 min at ambient temper-
ature. Adherent colonies were fixed to the membranes by being heated at
60°C for 15 min. After being washed twice in phosphate-buffered saline
(PBS) to remove excess cells, the filters were immersed in a solution of
trypsin (1 mg/ml) for 60 min at 37°C to remove protein A. After two
washes in PBS, the filters were blocked with 0.05% skim milk for 1 h and
washed in PBS containing 0.05% Tween 20 (PBST). Capsule type-specific
polyclonal antiserum (diluted 1:1,000) was incubated with each filter at
37°C for 1 h. After being washed in PBST, horseradish peroxidase-
conjugated goat anti-rabbit immunoglobulin was incubated with each
filter for 1 h at 37°C. After three washes in PBST and two washes in PBS,
substrate (3 mg 4-chloro-1-naphthol per ml of methanol diluted 1:5 in
PBS and containing 0.1% H2O2) was added to the filters. A purple color
developed within 15 min and was scored visually from 0 to 4. Positive
reactions were scored as 2 to 4. The reactivity of the isolates was
evaluated by comparison to those of control S. aureus strains (CP5,
CP8, and CP isolates) included on each filter membrane. Isolates with
no reaction to CP-specific antibodies were defined as CP.
USA300 strains subjected to whole-genome sequencing. To deter-
mine the basis for the CP5 phenotype, we analyzed the entire cap5 locus
from the WGS assemblies we produced (33) from 146 USA300 MRSA
isolates that were included in the sample tested for CP production. These
isolates were obtained between 2008 to 2010 from the University of Chi-
cago Medical Center (n 75) and Harbor-UCLA Medical Center in Los
Angeles (n 71) (44).
WGS and SNP calling. Genomic DNA was sequenced on an Illumina
HiSeq 2000 (Illumina Inc., San Diego, CA) at ~215 the median depth of
coverage per strain as described in reference 33 and the supplemental
material. Mutations in the cap5 locus were retrieved from the assemblies
by comparison to the cap5 locus of the CP5 reference strain Newman
using Jalview (45). All nucleotide positions are reported relative to the
USA300 reference strain TCH1516.
Confirmation of cap5mutations. To evaluate whether the conserved
mutations we identified in the WGS analysis were present in S. aureus
isolates of interest, the regions surrounding the mutations were PCR am-
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plified from the indicated strains using primers listed in Table 3. The
amplification products were subjected to Sanger sequencing in the DNA
sequencing and genotyping facility (University of Chicago) using the am-
plification primers. Mutations were identified using Vector NTI software
(Invitrogen) by alignment to the cap5 locus of the CP5 reference strain
Newman.
cap5 mutations in publicly available USA300 and non-USA300
S. aureus genomes. To examine whether the four cap5 locus mutations
found in the WGSs of our sample of 146 USA300 MRSA isolates were
universal in this clonal lineage, we also interrogated cap5 gene cluster
sequences from 319 publicly available USA300 MRSA genomes. These
included 35 isolates from San Diego (46), 277 isolates from New York City
(47), the completed genome sequences of strains TCH1516 (48), FPR3757
(49), UA-S391 (50), and ISMMS1 (51), and three isolates from Alam et al.
(52). Also, the phylogenetic distribution and origin of the cap mutations
among 90 publicly available non-USA300 S. aureus genomes from 41 STs
were studied using whole-genome alignment-based maximum likelihood
phylogeny of publicly constructed genomes using PhyML, as imple-
mented in REALPHY (53). Further details of the public sequence anno-
tations are provided in Table S2 in the supplemental material.
Complementation studies of the cap locus. In order to test the effect
of the cap5 mutations, we electrotransformed (54) a USA300 MRSA
strain, 923, with plasmids containing various cap5 genes that were isolated
from strain Newman and cloned into the vector pCU1 as summarized in
Table 4. Briefly we used pKOR18 (which contains cap5ABCD and a por-
tion of cap5E), pKOR19 (which contains cap5ABC and truncated cap5D)
(27), pCap16 (which contains intact cap5A-E) (35), and pCap17 (which
contains intact cap5A-F) (35). Following transformation, strain 923 was
cultured in the presence of chloramphenicol at 5 mg/liter to maintain the
plasmid. CP5 serotyping was performed as described above.
Nucleotide sequence accession number. The raw sequence reads
from the project have been deposited into the National Center for Bio-
technology Information (NCBI) Short Read Archive (SRA) database un-
der accession no. SRP039020. These sequences were also analyzed in ref-
erence 33.
SUPPLEMENTAL MATERIAL:
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.02585-14/-/DCSupplemental.
Text S1, DOCX file, 0.1 MB.
Figure S1, TIF file, 0.5 MB.
Table S1, PDF file, 0.1 MB.
Table S2, PDF file, 0.1 MB.
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